Spontaneous reporting--of what? Clinical concerns about drugs.
作者信息
Edwards I R
机构信息
The Uppsala Monitoring Centre, Stora Torget 3, 75320 Uppsala, Sweden.
出版信息
Br J Clin Pharmacol. 1999 Aug;48(2):138-41. doi: 10.1046/j.1365-2125.1999.00000.x.
Abstract
摘要
相似文献
1
Spontaneous reporting--of what? Clinical concerns about drugs.
Br J Clin Pharmacol. 1999 Aug;48(2):138-41. doi: 10.1046/j.1365-2125.1999.00000.x.
2
A database worth saving.
Lancet. 1997 Oct 11;350(9084):1045-6. doi: 10.1016/S0140-6736(05)70451-7.
3
Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration.
Pharmacotherapy. 2004 Jun;24(6):743-9. doi: 10.1592/phco.24.8.743.36068.
4
Monitoring the safety of over the counter drugs. We need a better way than spontaneous reports.
BMJ. 2001 Sep 29;323(7315):706-7. doi: 10.1136/bmj.323.7315.706.
5
Prescription-event monitoring and reporting of adverse drug reactions.
Lancet. 2001 Dec 1;358(9296):1872-3. doi: 10.1016/S0140-6736(01)06898-2.
6
"Yellow card" announcement used to head off concerns, experts claim.
BMJ. 2003 Aug 9;327(7410):308. doi: 10.1136/bmj.327.7410.308-a.
7
Reporting of adverse drug reactions: practice in the UK.
Nurs Times. 1998;94(10):52-4.
8
The role of pharmacists in adverse drug reaction reporting.
Drug Saf. 1994 Jul;11(1):7-11. doi: 10.2165/00002018-199411010-00002.
9
Veterinary pharmacovigilance. Part 2. Veterinary pharmacovigilance in practice -- the operation of a spontaneous reporting scheme in a European Union country -- the UK, and schemes in other countries.
J Vet Pharmacol Ther. 2005 Apr;28(2):149-70. doi: 10.1111/j.1365-2885.2005.00646.x.
10
Nurse reporting of adverse events caused by medicines.
Nurs Times. 2003;99(49):24-5.
引用本文的文献
1
Editorial: Traditional and innovative approaches for signal detection.
Front Drug Saf Regul. 2024 Feb 6;4:1373689. doi: 10.3389/fdsfr.2024.1373689. eCollection 2024.
2
Sports nutrition supplements and adverse events - a meta-epidemiological study of case reports specifically addressing causality assessment.
Eur J Clin Pharmacol. 2022 Jan;78(1):1-9. doi: 10.1007/s00228-021-03223-9. Epub 2021 Oct 2.
3
Signal Detection in EUROmediCAT: Identification and Evaluation of Medication-Congenital Anomaly Associations and Use of VigiBase as a Complementary Source of Reference.
Drug Saf. 2021 Jul;44(7):765-785. doi: 10.1007/s40264-021-01073-z. Epub 2021 May 9.
4
Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.
BioDrugs. 2018 Dec;32(6):607-617. doi: 10.1007/s40259-018-0313-2.
5
Did the New Italian Law on Mandatory Vaccines Affect Adverse Event Following Immunization's Reporting? A Pharmacovigilance Study in Southern Italy.
Front Pharmacol. 2018 Sep 4;9:1003. doi: 10.3389/fphar.2018.01003. eCollection 2018.
6
Data Mining for Adverse Drug Events With a Propensity Score-matched Tree-based Scan Statistic.
Epidemiology. 2018 Nov;29(6):895-903. doi: 10.1097/EDE.0000000000000907.
7
Comparison of online reporting systems and their compatibility check with respective adverse drug reaction reporting forms.
Indian J Pharmacol. 2017 Sep-Oct;49(5):374-382. doi: 10.4103/ijp.IJP_733_16.
8
Severe Secondary Polycythemia in a Female-to-Male Transgender Patient While Using Lifelong Hormonal Therapy: A Patient's Perspective.
Drug Saf Case Rep. 2018 Feb 2;5(1):6. doi: 10.1007/s40800-018-0075-2.
9
The hope, hype and reality of Big Data for pharmacovigilance.
Ther Adv Drug Saf. 2018 Jan;9(1):5-11. doi: 10.1177/2042098617736422. Epub 2017 Oct 31.
10
Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?
Clin Drug Investig. 2017 May;37(5):415-422. doi: 10.1007/s40261-017-0503-6.
本文引用的文献
1
Reasons for reporting adverse drug reactions--some thoughts based on an international review.
Pharmacoepidemiol Drug Saf. 1997 Jan;6(1):21-6. doi: 10.1002/(SICI)1099-1557(199701)6:1<21::AID-PDS259>3.0.CO;2-I.
2
The New Zealand Intensive Medicines Monitoring Programme.
Pharmacoepidemiol Drug Saf. 1998 Mar;7(2):79-90. doi: 10.1002/(SICI)1099-1557(199803/04)7:2<79::AID-PDS330>3.0.CO;2-1.
3
Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.
JAMA. 1998 Apr 15;279(15):1200-5. doi: 10.1001/jama.279.15.1200.
4
Causal or casual? The role of causality assessment in pharmacovigilance.
Drug Saf. 1997 Dec;17(6):374-89. doi: 10.2165/00002018-199717060-00004.
5
Who cares about pharmacovigilance?
Eur J Clin Pharmacol. 1997;53(2):83-8. doi: 10.1007/s002280050342.
6
Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. The European Pharmacovigilance Research Group.
Eur J Clin Pharmacol. 1997;52(6):423-7. doi: 10.1007/s002280050314.
7
Reporting of adverse drug reactions by hospital pharmacists: pilot scheme.
BMJ. 1997 Aug 30;315(7107):519. doi: 10.1136/bmj.315.7107.519.
8
Temporal trends in spontaneous reporting of unlabelled adverse drug reactions.
Br J Clin Pharmacol. 1997 Sep;44(3):299-301. doi: 10.1046/j.1365-2125.1997.t01-1-00573.x.
9
Principles of signal detection in pharmacovigilance.
Drug Saf. 1997 Jun;16(6):355-65. doi: 10.2165/00002018-199716060-00002.
10
Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture 1994.
J R Coll Physicians Lond. 1995 Jan-Feb;29(1):41-9.
Zotero 插件